Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
Novartis has received European Commission approval for Rhapsido (remibrutinib), the first oral targeted therapy for chronic spontaneous urticaria.
The company has also secured World Health Organization prequalification for Coartem Baby, an antimalarial developed for newborns and infants.
These twin regulatory milestones arrive as Novartis (SWX:NOVN) trades around CHF114.08, with the share price up 5.1% year to date and 25.9% over the past year. Over three and five years, the stock has returned 46.3% and 84.3% respectively, which helps frame how the market has treated the company while it has been building its current treatment portfolio.
For readers tracking longer term themes, Rhapsido adds an oral option in chronic spontaneous urticaria, while Coartem Baby targets a very young and often underserved patient group. Together, these products broaden the therapy mix across specialty care and global health. These are factors that investors may watch alongside the existing performance of SWX:NOVN.
Stay updated on the most important news stories for Novartis by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novartis.
SWX:NOVN Earnings & Revenue Growth as at Apr 2026
We’ve flagged 1 risk for Novartis. See which could impact your investment.
Investor Checklist Quick Assessment
✅ Price vs Analyst Target: At CHF114.08, the share price is about 6% below the CHF120.89 analyst target range midpoint.
✅ Simply Wall St Valuation: Shares are flagged as undervalued, trading 60.3% below an internal fair value estimate.
❌ Recent Momentum: The stock has seen a 4.2% decline over the last 30 days.
There is only one way to know the right time to buy, sell or hold Novartis. Head to the Simply Wall St’s company report for the latest analysis of Novartis’s Fair Value..
Key Considerations
📊 Rhapsido and Coartem Baby approvals extend Novartis’s reach across specialty allergy care and infant malaria treatment, which may influence how investors view its product depth.
📊 Watch how uptake of these products feeds into revenue, margins and whether the current P/E of 19.8, below the 37.5 industry average, persists.
⚠️ One flagged risk is a high level of debt, which investors may want to weigh against any additional investment needed to support launch and global roll out.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Novartis analysis. Alternatively, you can check out the community page for Novartis to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVN.SW.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com